Literature DB >> 17530506

Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone.

Douglas W Mapel1, Leila S Nelson, Eva Lydick, Joan Soriano, Marianne Ulcickas Yood, Kourtney J Davis.   

Abstract

Recent retrospective studies have suggested that use of inhaled corticosteroids (ICS) may improve survival in chronic obstructive pulmonary disease (COPD), particularly when combined with a long-acting beta-agonist (LABA). However, the study methodologies have been questioned, and no study has examined the survival effect of the newer combination ICS/LABA inhalers. The goal of this project was to further examine the relationship between ICS treatment, with or without LABA, and survival in COPD. COPD patients were identified from the administrative databases of four different integrated health care delivery systems. All patients who were diagnosed with COPD between September 1, 2000 and August 31, 2001 and who had at least 3 months treatment with either a combined fluticasone/salmeterol inhaler (FSI, N=866), any ICS used with a LABA (ICS/LABA, N=525), ICS alone (N=742), LABA alone (N=531), or a short-acting bronchodilator alone (SABD, N=1832), were included. Analyses were conducted using three different analysis approaches that adjust for various biases that may affect the results. In the basic Cox proportional hazards models, use of FSI, ICS/LABA, ICS alone, and LABA alone had significant survival benefits as compared to SABD, after adjustment for differences in age, gender, comorbidities, asthma status, and disease severity (HRs 0.61 [0.45-0.83], 0.59 [0.46-0.77], 0.76 [0.61-0.95], 0.75 [0.57-0.98], respectively). Propensity score matching to reduce the clinical differences between the treatment groups versus the SABD reference group found very similar results. Nested case-control analyses, which are based on survival status instead of treatment, continued to show a significant survival benefit for FSI, ICS/LABA, and ICS alone. Treatment with FSI or another ICS with or without LABA is associated with improved survival in COPD. The treatment benefit is reproducible and is robust to application of a number of different analysis techniques designed to adjust for differences in confounding variables and for bias by indication.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17530506     DOI: 10.1080/15412550701341111

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  9 in total

1.  Salmeterol combined with fluticasone propionate improved COPD in patients during stable stage.

Authors:  Dongmei Lu; Junpeng Ma; Xiaohong Yang
Journal:  Int J Clin Exp Med       Date:  2014-09-15

2.  Asthma, airflow limitation and mortality risk in the general population.

Authors:  Shuang Huang; Monica M Vasquez; Marilyn Halonen; Fernando D Martinez; Stefano Guerra
Journal:  Eur Respir J       Date:  2014-10-16       Impact factor: 16.671

3.  Inhaled Bronchodilators and Corticosteroids in the Management of Bronchiolitis Obliterans due to Allogenic Hematopoietic Stem Cell Transplantation.

Authors:  Vasiliki Epameinondas Georgakopoulou; Aikaterini Gkoufa; Nikolaos Garmpis; Anna Garmpi; Christos Damaskos
Journal:  Oman Med J       Date:  2022-05-31

Review 4.  Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease.

Authors:  Gillian M Keating; Paul L McCormack
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 5.  The role of fluticasone propionate/salmeterol combination therapy in preventing exacerbations of COPD.

Authors:  Barbara P Yawn; Ibrahim Raphiou; Judith S Hurley; Anand A Dalal
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-06-03

Review 6.  Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines.

Authors:  Hannu Kankaanranta; Terttu Harju; Maritta Kilpeläinen; Witold Mazur; Juho T Lehto; Milla Katajisto; Timo Peisa; Tuula Meinander; Lauri Lehtimäki
Journal:  Basic Clin Pharmacol Toxicol       Date:  2015-01-22       Impact factor: 4.080

Review 7.  The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease.

Authors:  Marc L Decramer; Nicola A Hanania; Jan O Lötvall; Barbara P Yawn
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-01-25

Review 8.  Asthma and COPD Overlap Syndrome (ACOS): A Systematic Review and Meta Analysis.

Authors:  A Alshabanat; Z Zafari; O Albanyan; M Dairi; J M FitzGerald
Journal:  PLoS One       Date:  2015-09-03       Impact factor: 3.240

9.  Inhaled therapies for chronic obstructive pulmonary disease: a systematic review and meta-analysis.

Authors:  Eleanor L Axson; Adam Lewis; James Potts; Marie Pang; Scott Dickinson; Helene Vioix; Jennifer K Quint
Journal:  BMJ Open       Date:  2020-09-29       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.